{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-26-004991","form_type":"8-K","ticker":"VNRX","cik":"0000093314","company_name":"VOLITIONRX LTD","filed_at":"2026-08-13T20:32:38+00:00","discovered_at":"2026-08-13T20:34:05.610133+00:00","generated_at":"2026-08-13T20:34:23.764351+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"VolitionRx Q2 2026: H1 revenue up 112% to $1.4M, operating loss down 34%","bullets":["H1 2026 revenue $1.4M, up 112% YoY; Q2 revenue ~$0.4M, flat YoY.","Q2 operating loss $4.2M, down 34% YoY; operating expenses down 32%.","Net cash used in ops $5.2M in Q2, down 18% YoY; raised $5.3M from equity sales.","In talks with 12+ diagnostic/liquid biopsy firms for licensing; Sysmex collaboration announced.","Nu.Q Vet feline assay manuscript submitted; publication could unlock $5M milestone."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-26-004991","json":"https://secwatch.observer/filing/0001477932-26-004991.json","markdown":"https://secwatch.observer/filing/0001477932-26-004991.md","text":"https://secwatch.observer/filing/0001477932-26-004991.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/93314/000147793226004991/0001477932-26-004991-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/93314/000147793226004991/vnrx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:34:23.764351+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}